2023年报医药生物（A股）上市公司市值战略研究报告-2024.6-102页

IIIIIIIIVVVIVII一、医药生物上市公司资本市场仍在下滑周期1.11.1.1300202412021.1.1-2024.4.30A30020%2022-01-202023-02-142024-03-0410%沪深3000%300-10%-20%-30%-40%-50%2021-01-04医药生物Choice43022021202220232024Choice120212021202443037.5%54.8%62.9%7%30.2%202119.8%202213.7%20232.7%20244303.4%20217.5%202218.8%20238.1%20247.0%202128.8%202218.5%20233.4%20240.4%202117.4%202228.1%20238.6%202417.1%20217.5%202222.4%202324.0%202425.2%202115.8%20224.2%202312.1%20241.8%32021202220232024430Choice30A44120234302022447920244230493643337455961970145.88155.66125.705079.11%20242%4301000848106500~1000112%200~500710%100~2008617%50~10022%20~5018137%10~20469%101%8939079.11%420244302022202320018140%35%18030%25%16020%15%14010%5%1201060%86100以下10亿8060464840207118010~20亿20~50亿100亿200亿500亿~1000亿以上50~100~200~5001000亿以下10~20亿20~50亿100亿200亿500亿~1000亿以上10亿50~100~200~5001000亿2022-04-302023-04-302024-04-30Choice31.1.352023TOP302024.4.30Choice41.2“高估值、低盈利”的行业特性，对未来业绩释放提出更高要求1.2.1=6Copyright©2024A57Choice1.2.21.2.2.1208Choice61.2.2.2209Choice71.2.2.3“”2010Choice81.2.2.4“”“”2011Choice91.2.2.5“”2012Choice101.2.2.620“”13Choice111.3142021-2023Choice121.3.22023202380.70115.8296.07TOP30152023Choice131.3.31/3162021-2024430PE300602022-01-202023-02-142024-03-0450沪深3004030201002021-01-04医药生物...